1. Home
  2. LRE vs XCUR Comparison

LRE vs XCUR Comparison

Compare LRE & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lead Real Estate Co. Ltd

LRE

Lead Real Estate Co. Ltd

HOLD

Current Price

$1.31

Market Cap

16.8M

Sector

N/A

ML Signal

HOLD

XCUR

Exicure Inc.

HOLD

Current Price

$2.40

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LRE
XCUR
Founded
2001
2011
Country
Japan
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.8M
13.7M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
LRE
XCUR
Price
$1.31
$2.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
12.7K
29.8K
Earning Date
07-30-2015
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
83.37
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.16
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.00
$1.71
52 Week High
$2.86
$9.50

Technical Indicators

Market Signals
Indicator
LRE
XCUR
Relative Strength Index (RSI) 53.60 40.86
Support Level $1.17 $1.71
Resistance Level $1.37 $3.50
Average True Range (ATR) 0.07 0.38
MACD -0.00 0.01
Stochastic Oscillator 78.57 52.01

Price Performance

Historical Comparison
LRE
XCUR

About LRE Lead Real Estate Co. Ltd

Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa Prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment units to individual customers in Japan and Dallas, Texas. Its revenue is predominantly generated from developing and selling single-family homes and condominiums, hotel operations, and residential leasing. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: